[go: up one dir, main page]

WO2001005763A2 - Composes possedant une activite sur les recepteurs muscariniques - Google Patents

Composes possedant une activite sur les recepteurs muscariniques Download PDF

Info

Publication number
WO2001005763A2
WO2001005763A2 PCT/US2000/019366 US0019366W WO0105763A2 WO 2001005763 A2 WO2001005763 A2 WO 2001005763A2 US 0019366 W US0019366 W US 0019366W WO 0105763 A2 WO0105763 A2 WO 0105763A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound
alkoxy
composition
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/019366
Other languages
English (en)
Other versions
WO2001005763A3 (fr
Inventor
Mark Brann
Terri Messier
Erika Currier
Kate Duggento
Mikael Friberg
Niels Skjaerbaek
Tracy Spalding
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acadia Pharmaceuticals Inc
Original Assignee
Acadia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharmaceuticals Inc filed Critical Acadia Pharmaceuticals Inc
Priority to AU61030/00A priority Critical patent/AU6103000A/en
Publication of WO2001005763A2 publication Critical patent/WO2001005763A2/fr
Anticipated expiration legal-status Critical
Publication of WO2001005763A3 publication Critical patent/WO2001005763A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms

Definitions

  • the present invention relates to novel compounds which are selective for muscarinic acetylchol ⁇ ne receptor subtypes, as well as to methods for activating muscarmic receptors and for treating or alleviating diseases in which modification of muscarinic receptor activity is beneficial.
  • Muscarinic acetylcholine receptors play a central role in the central nervous system for higher cognitive functions, as well as in the peripheral parasympathetic nervous system. Cloning has established the presence of five distinct muscarinic receptor subtypes (termed ml-m5) (cf. T.I. Bonner et al, Science 237, 1987, pp. 527- 532; T.I. Bonner et al., Neuron 1, 1988, pp. 403-410).
  • ml is the predominant subtype in the cerebral cortex and is believed to be involved in the control of cognitive functions
  • m2 is predominant in heart and is believed to be involved in the control of heart rate
  • m3 is believed to be involved in gastrointestinal and urinary tract stimulation as well as sweating and salivation
  • m4 is present in brain
  • m5 is present in brain and may be involved certain functions of the central nervous system associated with the dopaminergic system.
  • muscarinic ligands Animal studies of various muscarinic ligands (S. Iversen, Life Sciences 60 (Nos. 13/14). 1997, pp. 1145-1152) have shown that muscarinic compounds have a profound effect on cognitive functions, e.g. learning and memory. This would suggest a potential utility of muscarinic agonists in the improvement of cognitive functions in diseases characterized by cognitive impairment, both age-related (such as Alzheimer's disease or other dementias) and not age-related (such as attention deficit hyperactivity disorder).
  • age-related such as Alzheimer's disease or other dementias
  • attention deficit hyperactivity disorder such as attention deficit hyperactivity disorder
  • muscarinic receptor subtype is the more abundant one in the cerebral cortex, basal ganglia and hippocampus where it accounts for 35-60% of all muscarinic receptor binding sites (cf. A. Levey, Proc. Natl. Acad. Sci. USA 93. 1996, pp. 13541- 13546).
  • the ml (and possibly m4) subtype plays a major role as a postsynaptic muscarinic receptor (located on cholinoceptive neurons in the neocortex and hippocampus) in various cognitive and motor functions and is likely to be a major contributor to the ml responses measured in these regions of the brain.
  • conditions associated with cognitive impairment such as Alzheimer's disease, are accompanied by selective loss of acetylcholine in the brain. This is believed to be the result of degeneration of cholinergic neurons in the basal forebrain which innervate areas of the association cortex and hippocampus involved in higher processes (cf. S. Iversen, supra). This finding would suggest that such conditions may be treated or at least ameliorated with drugs that augment the cholinergic function in the affected areas of the brain.
  • acetylcholine esterase (AChE) inhibitors such as 9-amino- 1,2,3,4- tetrahydroacrid ⁇ ne (tacrine) results in an increase of acetylcholine in the brain which indirectly causes stimulation of muscarinic receptors.
  • Tacrine treatment has resulted in a moderate and temporary cognitive improvement in Alzheimer's patients (cf. Kasa et al., supra).
  • tacrine has been found to have cholinergic side effects due to the peripheral acetylcholine stimulation. These include abdominal cramps, nausea, vomiting, diarrhea, anorexia, weight loss, myopathy and depression. Gastrointestinal side effects have been observed in about a third of the patients treated.
  • Tacrine has also been found to cause significant hepatotoxicity, elevated hver transaminases having been observed in about 30% of the patients (cf. P. Taylor, "Anticholinergic Agents", Chapter 8 in Goodman and Gilman: The Pharmacological Basis of Therapeutics, 9 th Ed., 1996, pp. 161-176).
  • the adverse effects of tacrine have severely limited its clinical utility.
  • Another AChE inhibitor, (R,S)-l-benzyl-4-[5,6- dimethoxy-l-indanon-2yl]methylpiperidine.HCl (donepezil) has recently been approved for the treatment of symptoms of mild to moderate Alzheimer's disease (cf. P. Kasa et al, supra). No hepatic damage has been observed for this compound but it has gastrointestinal effects similar to those of tacrine, probably due to stimulation of the m3 receptor caused by elevated parasympathetic tone.
  • muscarinic agonists (believed to be ml selective) hitherto suggested for the treatment of Alzheimer's disease, such as arecoline, have not shown greater efficacy in clinical trials than AChE inhibitors (cf. S.V.P. Jones et al, supra).
  • arecoline was found to have not so much cognitive enhancing effects as effects on behavioral changes often observed in Alzheimer's disease patients, such as a significant increase in motor activity, significant uplifting of mood, and significant decrease in anergia.
  • ml agonists have later been found to be weak partial agonists selective for the m2 and/or m3 receptor subtypes (H. Brauner-Osborne et al., J. Med. Chem. 38, 1995, pp. 2188-2195).
  • m2 subtype selectivity is presumed to be responsible for the cardiovascular effects observed for these agonists, e.g. tachycardia and bradycardia. and m3 activity is believed to account for the adverse gastrointestinal effects of the agonists.
  • m2 and/or m3 activity is therefore a significant drawback for the muscarinic agonists proposed until now for the treatment of Alzheimer's disease, severely limiting the doses of the drugs which it has been possible to administer to patients who may therefore have received sub-optimal doses.
  • the lack of subtype select ty and low potency of the currently tested cholinergic compounds appear to favor the negative peripheral side effects and have limited cognitive effects because of weak and/or opposing actions in the brain. It would therefore be of great advantage to develop compounds which have an improved selectivity for the ml subtype, but which have little or no activity on the m2 and m3 subtypes.
  • the present invention provides compounds with muscarinic agonist activity of the general formula (I):
  • Xi. X 2 . X 3 . X 4 and X 5 are selected from C, N and O; k is 0 or 1 ; t is 0. 1 or 2;
  • Ri is straight or branched-chain C 1-8 alkyl.
  • C 5-6 aryl or C -6 cycloalkyl optionally comprising 1 or more heteroatoms selected from N, S and O; -C(O)NR 3 R 4 .
  • Rj and R 5 are the same or different, each independently being selected from H, C ⁇ - ⁇ , alkyl: C . ⁇ aryl optionally comprising 1 or more heteroatoms selected from N. O and
  • A is C 5- ⁇ aryl or C 5- 7 cycloalkyl, each optionally comprising 1 or more heteroatoms selected from N. S and O;
  • R 2 is H. amino. hydroxyl, halo, or straight or branched-chain C ⁇ -6 alkyl, C -t , alkenyl. C 2- 6 alkynyl. C ⁇ -6 alkoxy. C ⁇ -6 heteroalkyl, Cj. 6 aminoalkyl, C !-6 haloalkyl. C 1 - 6 alkylthio. C ⁇ -6 alkoxvcarbonyl. -CN, -CF 3 . -OR 3 . -COR 3 . NO 2 , -NHR 3 . -
  • Z is CRsR 9 wherein R 8 and R9 are independently selected from H, and straight or branched chain C ⁇ -8 alkyl; or a pharmaceutically acceptable salt, ester or prodrug thereof.
  • the present invention further provides pharmaceutical compositions comprising an effective amount of a compound of formula (I).
  • the present invention provides a method of treating the symptoms of a disease or condition associated with increased intraocular pressure, such as, for example, glaucoma, where the method comprises administering a therapeuticaUy effective amount of a composition comprising a compound of formula
  • Figure 1 is a graph showing raw data from one 96-well microtiter plate of screening of 35.000 small organic molecules in the assay described in Example XVI.
  • Figure 2 is a graph showing data comparing the profile of the reference antagonist atropine with ml muscarinic receptor transfected cells stimulated with either carbachol (open triangles) or compound A (Example I) (closed triangles).
  • the present invention provides compounds preferably showing a relatively high selectivity towards the ml receptor subtype relative to other muscarinic subtypes which may have a beneficial effect in the treatment of cognitive impairment such as Alzheimer's disease or other conditions associated with age-related cognitive decline while avoiding the adverse affects of the drugs hitherto suggested for this purpose.
  • Compounds exhibiting this property have surprisingly been isolated by screening against ml-m5 receptor subtypes.
  • the present invention provides compounds of formula (I), wherein Xi, X 2 , X 3 , t and X 5 are C; or one of Xi, X 2 , X 3 , X 4 or X 5 is O or N and the others are C; k is 0 or 1 ; t is 1; Ri is straight or branched-chain C 1-8 alkyl, C 2-8 alkenyl, C 2-8 alkynyl, C ⁇ -8 alkylidene, C ⁇ -8 alkoxy, C ]-8 aminoalkyl, C ⁇ -8 haloalkyl, C ⁇ -8 alkoxycarbonyl, -C(O)NR 3 R 4 , -NR 3 R4, -NR 3 C(O)NR4R 5 , -OC(O)R 3 , or -(CH 2 ) S NR 3 R 4 ; where R 3 , P and R 5 are the same or different, each independently being selected from H and Ci- ⁇ al
  • A is phenyl or naphthyl; where R 2 is straight or branched-chain C ⁇ -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, d -6 alkoxy, C ]-6 aminoalkyl, C ⁇ -6 haloalkyl, C 1-6 alkoxycarbonyl, -CN, -CF 3 , -OH, -COR 3 , -NHR 3 , -NHC(O)R 3 , -C(O)NR 3 R4, -NR 3 R4, -NR 3 C(O)NR4R 5 , -OC(O)R 3 , or -CH 2 ) q NR 3 R ; where q is an integer from 1 to 6; or
  • A is aryl comprising 1 or more heteroatoms selected from N, S and O;
  • R 2 is H, halo, straight or branched-chain C ⁇ -6 alkyl, C 2-6 alkenyl, C -6 alkynyl, C ]-6 alkoxy, C ]-6 heteroalkyl, C ⁇ -6 aminoalkyl, C ⁇ -6 haloalkyl, C ⁇ -6 alkoxycarbonyl, -CN, - CF 3 , OH. -COR3, -NHR 3 , -NHC(O)R 3 , -C(O)NR 3 R 4 , -NR 3 R 4 , -OC(O)R 3 a pharmaceutically acceptable salt, ester or prodrug thereof.
  • the compound is of the formula (II):
  • Preferred subgeneric embodiments of compounds of formula (II) include compounds of formulas (Ila) and (lib): R 2
  • t is 1 and Y is -C(O)-, -NHC(O)-, S, O or -OC(O)-.
  • X 3 is C.
  • Ri is alkyl, where preferably R 2 is alkyl, aminoalkyl. alkoxy or hydroxyl. In one embodiment, p is 3. In another, Ri is C 2- alkyl and R 2 is methyl, hydroxyl or alkoxy.
  • n is 1 or 2; Y is -C(O)- or O and t is 1.
  • R 2 is halo.
  • X 3 may also be N, where according to one embodiment, Ri is alkyl or alkoxy; or Ri is benzyl or phenyl; where R 2 is alkyl or alkoxy.
  • X 3 is O, where t may be, for example, 0.
  • R 2 is alkyl or alkoxy; or R is halo.
  • Particular embodiments of the invention include: 4-Methoxy- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine: 4-Ethoxy- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine; 4-Propoxy- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine; 4-Butoxy- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine; 4-Methoxymethyl-l-[4-(2-methylphenyl)-4-oxo-l -butyljpiperidine; 4-Ethoxymethyl- 1 -[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine: 4-Propoxymethyl-l-[4-(2-methylphenyl)-4-oxo- 1 -butyljpiperidine: 4-
  • (CH 2 ) P -Y- is -(CH 2 ) 3 -C(O)- or -(CH 2 ) 3 -S-; and X, through X 5 are C; such that -A-
  • R 2 ⁇ and Ri are not together: o-methyl-phenyl and n-butyl, respectively; phenyl and n-butyl. respectively; or p-fluoro-phenyl and -O-(CH 2 ) 2 CH 3 , respectively).
  • the present invention further provides a method of agonizing a muscarinic receptor comprising contacting the receptor with an effective amount of a compound of formula (I), inclusive of all compounds within the scope of formula (I)(i.e., including 4-72-Butyl- 1 -[4-phenyl-4-oxo-l -butyljpiperidine; 4-72-Butyl- 1 -[4-(2- methylphenyl)-4-oxo-l -butyl] piperazine; 2-[3-(3-72-Butylpiperidine)propanesulfanyl] toluene; and 4-Propyloxy-l-[4-(4-fluorophenyl)-4-oxo-l-butyl]piperidine).
  • a compound of formula (I) inclusive of all compounds within the scope of formula (I)(i.e., including 4-72-Butyl- 1 -[4-phenyl-4-oxo-l -buty
  • compositions comprising an effective amount of a compound of formula (I), inclusive of all compounds within the scope of formula (I)(i.e., including -72-Butyl-l-[4-phenyl-4-oxo-l -butyljpiperidine; 4- ⁇ z-Butyl- l-[4-(2-methylphenyl)-4-oxo-l-butyljpiperazine; 2-[3-(3-7?-
  • the present invention further also provides methods of treating the symptoms of a disease or condition associated with reduced levels of acetylcholine, the method comprising administering a therapeuticaUy effective amount of a composition described herein.
  • diseases or conditions include neurogenerative disease, cognitive impairment, age-related cognitive decline or dementia.
  • Glaucoma is a disease in which an abnormality is observed in the circulation-control mechanism of the aqueous humor filling up the anterior chamber, i.e., the space formed between the cornea and the lens. This leads to an increase in the volume of the aqueous humor and an increase in intraocular pressure, consequently leading to the visual field defect and even to loss of eyesight due to the compulsion and contraction of the papillae of the optic nerve.
  • the compounds of the present invention preferably show selective agonist activity towards the ml receptor.
  • Such an agonist is defined as a compound that increases the activity of the ml muscarinic receptor when it contacts the receptor.
  • Selectivity is defined as a property of a muscarinic ml agonist whereby an amount of agonist effective to increase the activity of the ml receptor causes little or no increase in the activity' of the m3 and m5 subtypes, and preferably the m2 and m4 subtypes.
  • alkyl means a straight or branched-chain alkane group with 1-6 carbon atoms in the chain, for instance methyl, ethyl, propyl, isopropyl, n- butyl, sec-butyl, tert-butyl, etc.
  • heteroalkyl is intended to indicate an alkane group containing 1 or 2 heteroatoms selected from O, S or N.
  • alkenyl means a straight or branched-chain alkene group with 2-6 carbon atoms in the chain; the term “alkynyl” is intended to indicate a straight or branched-chain alkyne group with 2-6 carbon atoms in the chain.
  • aryl and “cycloalkyl” preferably refer to mono- and bicyclic ring structures comprising 5 to 12 carbon atoms, more preferably monocyclic rings comprising 5 to 6 carbon atoms. Where such rings comprise one or more heteroatoms, selected from N, S and O, (i.e., heterocyclic rings) such rings comprise a total of 5 to 12 atoms, more preferably 5 to 6 atoms.
  • Heterocyclic rings include, but are not limited to, furyl, pyrrolyl, pyrazolyl, thienyl, imidazolyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, pyridyl, piperidinyl, piperazinyl, pyridazinyl, pyrimidinyl, pyrazinyl, morpholinyl, oxadiazolyl, thiadiazolyl, imidazolinyl, imidazolidinyl and the like.
  • the ring may be substituted by one or more of the groups included in the definition of R above.
  • substituents d- ⁇ alkyl, C ⁇ -6 alkenyl, d- 6 alkynyl, C 1-6 alkoxy, C 1-6 heteroalkyl, C ⁇ - aminoalkyl, C 1-6 haloalkyl or C ⁇ -6 alkoxycarbonyl may, if present, be substituted by one or more of hydroxyl, C alkoxy, halogen, cyano, amino or nitro.
  • halogen or halo includes chlorine, fluorine, iodine and bromine.
  • 2 x ⁇ may be both saturated and unsaturated.
  • the starting compound having formula (X) may be prepared by general methods of organic synthesis.
  • general methods of preparing compounds of formula (X) reference is made to Fuller, R. W. et al., J. Med. Chem. 14:322-325 (1971); Foye, W. O., et al., J. Pharm.Sci. 68:591-595 (1979); Bossier, J. R. et al., Chem. Abstr. 66:46195h and 67:21527a (1967); Aldous, F. A. B., J. Med. Chem. 17:1100-1111 (1974): Fuller, R. W. et al., J. Pharm. Pharmacol.
  • radiolabelled derivatives having formula (XX) may be prepared by, for example, using a tritiated reducing agent to form the reductive amination or by utilizing a 14 C-labelled starting material.
  • the compound having the formula (XXII) may be reduced with, for example, A1H 3 , diborane:methyl sulfide or other standard carbonyl reducing reagents to produce the ligand having the formula (XXX).
  • the receptor hgands having formula (XXXII) may be prepared by nucleophilic displacement of an elecfrophile (E) by the amino derivative (XXXI).
  • electrophiles which may be used for this purpose include halides such as I, Cl, Br, tosylate or mesylate.
  • this compound may be prepared from oxidation of an sec. alcohol with for example pyridinium chlorocromate or N- chlorosuccinimide or CrO 3 -H 2 SO or nickel peroxide or metal (Al, K) or DCC- DMSO.
  • this compound may be prepared by alkylation of an alcohol with arylhalides under for example Cu catalysis.
  • this compound When Y in formula (XXXTI) is -S-, this compound may be prepared by alkylation of a thiol with arylhalides under for example Cu catalysis.
  • Y in formula (XXXTI) is -CHOH-, this compound may be prepared by reduction of the corresponding ketone by catalytic hydrogenation or by the use of NaBFL; or by the use of LiAlfL;.
  • Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
  • suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g.
  • salts examples include the acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, carbonate, chloride, clavulanate, citrate, dihydrochloride, fumarate, gluconate, glutamate, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, nitrate, N-methylglucamine ammonium salt, oleate, oxalate, phosphate/diphosphate, salicylate, stearate, sulfate, succinate, tannate, tartrate, tosylate, triethiodide and valerate salt.
  • the present invention includes within its scope prodrugs of the compounds of this invention.
  • prodrugs are inactive derivatives of the compounds of this invention which are readily convertible 272 vivo into the required compound.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs,” ed. H. Bundgaard, Elsevier, 1985. Metabolites of these compounds include active species produced upon introduction of compounds of this invention into the biological milieu.
  • the compounds according to the invention may exist as a racemate or as enantiomers. It should be noted that all such isomers and mixtures thereof are included in the scope of the present invention. Furthermore, some of the crystalline forms for compounds of the present invention may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds of the present invention may form solvates with water (i.e., hydrates) or common organic solvents. Such solvates are also included in the scope of this invention.
  • the processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers, such isomers may be separated by conventional techniques such as preparative chiral chromatography.
  • the compounds may be prepared in racemic form, or individual enantiomers may be prepared either by stereoselective synthesis or by resolution.
  • the compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base.
  • the compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.
  • any of the processes for preparation of the compounds of the present invention it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991.
  • the protecting groups may be removed at a convenient subsequent stage using methods known from the art.
  • Compounds of the present invention may be administered in any of the foregoing compositions and according to dosage regimens established in the art whenever specific pharmacological modification of the activity of muscarinic receptors is required.
  • compositions comprising one or more compounds of the invention together with a pharmaceutically acceptable diluent or excipient.
  • compositions are in unit dosage forms such as tablets, pills, capsules (including sustained-release or delayed-release formulations). powders, granules, elixirs, tinctures, syrups and emulsions, sterile parenteral solutions or suspensions, aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral (e.g.
  • compositions may be in sustained-release form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection.
  • suitable topical formulations for administration e.g. eye or skin or mucosa.
  • the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
  • suitable binders, lubricants, disintegrating agents, flavoring agents and coloring agents can also be incorporated into the mixture.
  • suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or beta-lactose, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
  • Lubricants used in these dosage forms include, without limitation, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
  • a suitable pharmaceutical excipient e.g. such as the ones described above
  • other pharmaceutical diluents e.g. water
  • the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
  • the solid preformulation composition may then be subdivided into unit dosage forms of the type described above containing from 0.1 to about 50 mg of the active ingredient of the present invention.
  • the tablets or pills of the present composition may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
  • the tablet or pill can comprise an inner core containing the active compound and an outer layer as a coating surrounding the core.
  • the outer coating may be an enteric layer which serves to resist disintegration in the stomach and permits the inner core to pass intact into the duodenum or to be delayed in release.
  • a variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with conventional materials such as shellac, cetyl alcohol and cellulose acetate.
  • the liquid forms in which the present compositions may be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical carriers.
  • Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, gelatin, methylcellulose or polyvinyl-pyrrolidone. Other dispersing agents which may be employed include glycerin and the like.
  • sterile suspensions and solutions are desired.
  • Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.
  • the compositions can also be formulated as an ophthalmic solution or suspension formation, i.e., eye drops, for ocular administration
  • the present invention also relates to a method of alleviating or treating a disease or condition in which modification of muscarinic receptor activity, in particular ml receptor activity, has a beneficial effect by administering a therapeuticaUy effective amount of a compound of the present invention to a subject in need of such treatment.
  • diseases or conditions may, for instance arise from inadequate stimulation or activation of muscarinic receptors.
  • compounds which are selective for a particular muscarinic receptor subtype, in particular ml the problems with adverse side effects observed with the known muscarinic drugs, such as tachycardia or bradycardia or gastrointestinal effects, may substantially be avoided.
  • subject refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
  • therapeutically effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease being treated.
  • compounds of general formula I exhibit subtype selectivity for the muscarinic ml receptor subtype.
  • the compounds exhibit selectivity for the muscarinic ml receptor subtype compared to other human G-protein coupled receptors tested including serotonin, histamine, dopamine or adrenergic receptors.
  • selectivity is that these compounds may be effective in the treatment or amelioration of a number of diseases and disorders of the central nervous system without the undesirable side effects previously observed with non- selective compounds.
  • muscarinic ml receptor subtype selectivity makes them potentially very useful in treating a number of diseases and disorders characterized by cognitive impairment such as attention deficit disorder, or neurodegenerative diseases, e.g. Alzheimer's disease, other forms of age-related cognitive decline, e.g. senile dementia, or dementia-related symptoms such as decreased motor activity, mood changes, anergia, apathy, restlessness and aggressive behavior. It is currently believed that the muscarinic ml receptor may also be involved in control of intraocular pressure, and that muscarinic ml agonists may therefore be used to treat or alleviate ocular diseases such as glaucoma.
  • cognitive impairment such as attention deficit disorder, or neurodegenerative diseases, e.g. Alzheimer's disease, other forms of age-related cognitive decline, e.g. senile dementia, or dementia-related symptoms such as decreased motor activity, mood changes, anergia, apathy, restlessness and aggressive behavior.
  • muscarinic ml receptor may also
  • compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses two, three or four times daily.
  • compounds for the present invention may be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to persons skilled in the art.
  • the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
  • the dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound employed.
  • a physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the disease or disorder which is being treated.
  • the daily dosage of the products may be varied over a wide range from 0.01 to 100 mg per adult human per day.
  • compositions are preferably provided in the form of tablets containing 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0 or 50.0 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • a unit dose typically contains from about 0.001 mg to about 50 mg of the active ingredient, preferably from about 1 mg to about 10 mg of active ingredient.
  • An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.0001 mg/kg to about 25 mg/kg of body weight per day.
  • the range is from about 0.001 to 10 mg/kg of body weight per day, and especially from about 0.001 mg/kg to 1 mg/kg of body weight per day.
  • the compounds may be administered on a regimen of 1 to 4 times per day.
  • Compounds according to the present invention may be used alone at appropriate dosages defined by routine testing in order to obtain optimal pharmacological effect on a muscarinic receptor, in particular the muscarinic ml receptor subtype, while minimizing any potential toxic or otherwise unwanted effects.
  • co-administration or sequential administration of other agents which improve the effect of the compound may, in some cases, be desirable.
  • the pharmacological properties and the selectivity of the compounds of this invention for specific muscarinic receptor subtypes may be demonstrated by a number of different assay methods using recombinant receptor subtypes, preferably of the human receptors if these are available, e.g. conventional second messenger or binding assays.
  • a particularly convenient functional assay system is the receptor selection and amplification assay disclosed in US 5,707,798 describing a method of screening for bioactive compounds by utilizing the ability of cells transfected with receptor DNA, e.g. coding for the different muscarinic subtypes, to amplify in the presence of a ligand of the receptor. Cell amplification is detected as increased levels of a marker also expressed by the cells.
  • Example I 4-n-Butyl-l-[4-(2-methylphenyl)-4-oxo-l-butyl]piperidine (5) l-Benzyl-4-n-butylidenepiperidine (2).
  • a 500 mL 3-necked flask fitted with a stirrer. was charged with sodium hydride (1.61 g, 67 mmol) and DMSO (40 mL).
  • the resulting suspension was heated to 90°C for 30 min, until the evolution of hydrogen ceased.
  • the suspension was cooled on an ice-bath for 20 min followed by addition of a slum' of butyltriphenylphosphonium bromide (26.6 g, 67 mmol) in DMSO (70 mL).
  • Example II 3-Hydroxymethyl-[4-(2-methylphenyl)-4-oxo-l-butyl]piperidine (7) 4-(3-Hydroxymethyl-piperidin-l-yl)-butyronitrile (6).
  • piperidine-3-yl-methanol (1.12 g, 10 mmol) in acetonitrile (10 mL)
  • potassium carbonate (1.38 g, 10 mmol
  • 4- bromobutyronitrile (0.90 mL, 9 mmol).
  • the reaction mixture was stirred at rt. for 12 h.
  • the mixture was filtered and evaporated to dryness.
  • reaction mixture was quenched by addition of H 2 SO 4 (10 mL, 2 M) and stirred at rt for 12 hours followed by addition of NaOH (10 mL, 2 M).
  • Addition of THF (15 mL) was followed by extraction with ethyl acetate (3 x 50 mL) and the combined organic phases are washed with brine (10 mL) and NaOH (10 mL, 2 M), dried (MgSO 4 ) and evaporated to dryness to produce 0.43 g of crude 9.
  • Example VII 4-Methyl-l-[4-(2-methylphenyl)4-oxo-l-butyl]piperazine (15) 4-(4-Methyl-piperazin-l-yl)-butyronitrile (14).
  • 1- methyl-piperazine 0.52 g, 5.1 mmol
  • 4-bromobutyronitrile 0.78 g, 5.3 mmol
  • potassium carbonate 0.71 g, 5.3 mmol
  • reaction mixture was quenched by addition of H SO (7 mL, 2 M) and stirred at rt for 3 hours, followed by addition of NaOH (20 mL, 2 M) until basic conditions.
  • the reaction mixture was extracted with ethyl acetate (3 x 50 mL) and the combined organic phases are washed with brine (10 mL) and NaOH (10 mL, 2 M), and the organic phases were dried (MgSO 4 ) and evaporated to dryness to produce 0.69 g of crude 19.
  • the crude product was subjected to CC [eluent: CH 2 C1 2 : MeOH (99:1)] to give pure 19 (0.40 g, 64 %); LC-MS [M + Hf 315 (cald. 315.5).
  • reaction mixture was quenched by addition of H 2 SO 4 (8 mL, 2 M) and stirred at rt for 4 hours, then the reaction mixture was basif ⁇ ed by addition of NaOH (20 mL, 2 M).
  • Addition of THF (20 mL) was followed by extraction with ethyl acetate (3 x 50 mL) and the combined organic phases are washed with brine (10 mL) and NaOH (10 mL, 2 M), and the organic phases were dried (MgSO 4 ) and evaporated to dryness to produce 0.61 g of crude 20.
  • the crude product was subjected to CC [eluent: CH C1 : MeOH (99:1)] to give pure 20 (0.21 g.
  • the reaction mixture was basified by addition of NaOH (2 mL, 2.0 M) and filtered through celite.
  • the aqueous phase was extracted with ethyl acetate (3 x 50 mL) and the combined organic phases were washed with brine (10 mL) and NaOH (10 mL, 2 M), dried (MgSO 4 ) and evaporated to dryness to produce 0.42 g of crude 27.
  • the crude product was subjected to CC [eluent: : CH 2 C1 2 : MeOH (99:1)] to give pure 27 (0.21 g, 58 %); LC-MS [M+ Hj + 303 (cald. 303.2).
  • NTH 3T3 cells (available from the American Type Culture Collection as ATCC CRL 1658) were grown at 37°C in a humidified atmosphere (5% CO 2 ) incubator in Dulbecco's modified Eagle's medium (DMEM) supplemented with 4.5 g/l glucose, 4 mM glutamine, 50 units/ml penicillin, 50 units/ml streptomycin (available from Advanced Biotechnologies, Inc., Gaithersburg, MD) and 10% calf serum (available from Sigma, St. Louis, MI). The cells were treated with trypsin-EDTA, spun down and plated at 2xl0 6 per 15 cm dish in 20 ml of DMEM containing 10% calf serum.
  • DMEM Dulbecco's modified Eagle's medium
  • the ml-m5 muscarinic receptor subtypes were cloned substantially as described by Bonner et al., Science 237, 1987, p. 527, and Bonner et al., Neuron 1, 1988, p. 403.
  • the cells were co-transfected with DNA encoding a chimera between the Gq protein and the five carboxy-terminal amino acids of the Gi protein (the Gq-i5 construct is described by Conklin et al., Nature 363, 1993, p.274).
  • the cells were transfected using the Superfect transfection reagent (available from Qiagen, Valencia, CA) in accordance with the manufacturer's instructions.
  • 60 ⁇ l Superfect was added to the DNA and mixed thoroughly by pipetting up and down several times. The mixture was incubated at room temperature for 10-15 minutes.
  • the media were aspirated, and 12 ml fresh DMEM containing 10% calf serum and 50 units/ml penicillin/streptomycin was added to the plates.
  • the DNA-Superfect solution was mixed once more with a pipette and added to the plate which was swirled to distribute the DNA mixture evenly over the surface.
  • the cells were incubated overnight at 37°C and 5% CO 2 .
  • the media were aspirated and the plates were rinsed once with a 15 ml volume of Hank's Buffered Saline. The plates were swirled to ensure thorough rinsing. 20 ml fresh DMEM supplemented with 10% calf serum and 50 units/ml penicillin/streptomycin was added to the plates. The cells were incubated for 24-48 hours until the plates were 100% confluent.
  • DMEM containing 2% Cyto-SF3 was heated at 37°C in a water bath under sterile conditions.
  • Sterile working stock solutions of test compounds to be assayed were prepared by diluting the compounds in DMEM to 8x the final concentration for testing.
  • the compound (carbachol) to be included in the assay as a positive control was also diluted in DMEM to 8x the final concentration.
  • 50 ⁇ l of the DMEM containing 2% Cyto-SF3 was added to each well of 96-well microtiter plates under sterile conditions.
  • the cells were left in the incubator for about 10-15 minutes until the HBS had turned slightly yellow. The HBS was then aspirated and 1 ml trypsin was added to each plate and swirled so as to completely cover the plates. The edges of the plates were gently rapped several times to loosen the cells. After the cells had been dislodged from the surface, 8 ml DMEM containing 10% calf serum and 50 units/ml penicillin and 50 units/ml streptomycin was added to inhibit the trypsin. The plates were rinsed with this medium, and the cells were pipetted into a tube. The cells were centrifuged at 1000 rpm for 5-10 min. in an IEC Centra CL2 centrifuge (produced by Sorvall).
  • the cell pellet was suspended in 1600 ⁇ l DMEM containing 10% calf serum and 50 units/ml penicillin and 50 units/ml streptomycin, after which 20 ml DMEM supplemented with 2% Cyto-SF3 was added. 50 ⁇ l aliquots of this cell suspension was added to the wells of the 96-well microtiter plates prepared above (except for the plate control wells). The plates were then incubated for 4 days at 37°C and 5% CO 2 .
  • NTH 3T3 cells were co- transfected with DNAs encoding the ml, m3 and m5 receptor subtypes.
  • a compound library containing approximately 35,000 small organic compounds (1 per well) was screened against the receptors by the procedures described above.
  • Fig. 1 illustrates data from one 96-well plate from the screen. On this plate, two compounds were active at one or more of the transfected receptors. In the total screen, four related compounds were identified that showed activity. To determine which of the receptors were activated in the screen, the compounds were tested as described above against each of the receptors transfected into separate cell cultures. Compound A only activated the ml receptor subtype, at which it was a potent partial agonist, inducing a lower maximal response than the reference compound carbachol.
  • the four compounds were found to selectively activate the ml receptor with no significant activity at the m2, m3, m4 or m5 muscarinic receptors.
  • the most active compound, compound A was not an antagonist of carbachol-induced responses of the five muscarinic receptor subtypes.
  • Compound A was further tested for agonist activity against several other receptors at the ⁇ -adrenergic receptor subtypes ID, IB, 1A, 2A, 2B and 2C, the histamine HI and the serotonin 5-HT1A and 5-HT2A subtypes. The compound showed no significant activity in these assays. In antagonist experiments, compound A did not inhibit responses of the ⁇ -adrenergic receptor subtypes 2A, 2B or 2C, or the serotonin receptor subtypes 5-HT1A or 5-HT2A. As illustrated in Figure 2, the responses induced by compound A were blocked by the muscarinic antagonist atropine with the same potency as were responses induced by the muscarinic agonist carbachol.
  • R-SAT assays (see U.S. patent no. 5,707,798, incorporated herein by reference) were carried out where cells transfected with ml, m3 or m5 receptors were exposed to seven compounds at 1.5 ⁇ M concentration. Cellular response is expressed as a percentage of the maximum response of the cells (defined as response to 10 ⁇ M carbachol). The results are presented in the following table.
  • the compounds are selective agonists of the ml receptor.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés et procédés destinés à atténuer les effets de maladies ou pathologies ou traiter ces maladies ou pathologies, et consistant à modifier l'activité du récepteur m1 muscarinique, cette modification ayant un effet bénéfique. Dans ce procédé, on administre à un patient nécessitant un tel traitement une dose efficace d'un composé agoniste du récepteur m1 muscarinique.
PCT/US2000/019366 1999-07-16 2000-07-14 Composes possedant une activite sur les recepteurs muscariniques Ceased WO2001005763A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU61030/00A AU6103000A (en) 1999-07-16 2000-07-14 Compounds with activity on muscarinic receptors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/356,202 US6528529B1 (en) 1998-03-31 1999-07-16 Compounds with activity on muscarinic receptors
US09/356,202 1999-07-16

Publications (2)

Publication Number Publication Date
WO2001005763A2 true WO2001005763A2 (fr) 2001-01-25
WO2001005763A3 WO2001005763A3 (fr) 2002-01-17

Family

ID=23400557

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/019366 Ceased WO2001005763A2 (fr) 1999-07-16 2000-07-14 Composes possedant une activite sur les recepteurs muscariniques

Country Status (3)

Country Link
US (3) US6528529B1 (fr)
AU (1) AU6103000A (fr)
WO (1) WO2001005763A2 (fr)

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624162B2 (en) 2001-10-22 2003-09-23 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor modulators
WO2004063330A2 (fr) 2003-01-06 2004-07-29 Osi Pharmaceuticals, Inc. Composes de (2-carboxamido) (3-amino) thiophene
US6951867B2 (en) 2002-09-20 2005-10-04 Pfizer Inc. N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators
US6979690B2 (en) 2002-01-07 2005-12-27 Pfizer Inc. Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators
US7012080B2 (en) 2002-09-20 2006-03-14 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor agonists
WO2006047574A1 (fr) 2004-10-26 2006-05-04 Osi Pharmaceuticals, Inc. Composes de (2-carboxamido)(3-amino) thiophene
US7595329B2 (en) 2004-06-15 2009-09-29 Pfizer Inc Benzimidazolone carboxylic acid derivatives
US7659394B2 (en) 2004-04-30 2010-02-09 Pfizer Inc Substituted morpholine compounds for the treatment of central nervous system disorders
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
US7737142B2 (en) 2003-08-04 2010-06-15 Richter Gedeon Vegyeszeti Gyar Rt. (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
EP2258358A2 (fr) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
US8044207B2 (en) 2002-03-29 2011-10-25 Eli Lilly And Company Pyridinoylpiperidines as 5-HT1F agonists
WO2011139951A1 (fr) 2010-05-03 2011-11-10 Janssen Pharmaceutica Nv Modulateurs de l'amide hydrolase d'acide gras
US8097610B2 (en) 2005-08-26 2012-01-17 Shionogi & Co., Ltd. Derivative having PPAR agonistic activity
US8569498B2 (en) 2008-12-18 2013-10-29 Richter Gedeon Nyrt. Process for the preparation of piperazine compounds and hydrochloride salts thereof
US8569496B2 (en) 2008-12-17 2013-10-29 Richter Gedeon Nyrt. Piperazine salt and a process for the preparation thereof
US8569497B2 (en) 2008-12-18 2013-10-29 Richter Gedeon Nyrt. Process for the preparation of piperazine derivatives
US20140045863A1 (en) * 2008-05-15 2014-02-13 The Board Of Trustees Of The University Of Illinois Muscarinic Agonists as Cognitive Enhancers
US8697876B2 (en) 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
US8765765B2 (en) 2007-05-18 2014-07-01 Richter Gedeon Nyrt. Metabolites of (thio) carbamoyl-cyclohexane derivatives
US8802672B2 (en) 2007-12-03 2014-08-12 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
US8829028B2 (en) 2002-05-16 2014-09-09 Serodus As 5-HT4 receptor antagonists for the treatment of heart failure
US8912197B2 (en) 2012-08-20 2014-12-16 Forest Laboratories Holdings Ltd. Crystalline form of carbamoyl-cyclohexane derivatives
US9018214B2 (en) 2011-04-21 2015-04-28 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9169224B2 (en) 2004-12-30 2015-10-27 Janssen Pharmaceutica Nv Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
US9617248B2 (en) 2012-10-19 2017-04-11 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9617283B2 (en) 2012-10-19 2017-04-11 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9663512B2 (en) 2012-10-19 2017-05-30 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9783538B2 (en) 2013-12-20 2017-10-10 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US10000477B2 (en) 2014-10-31 2018-06-19 Indivior Uk Limited Dopamine D3 receptor antagonist compounds
EP3233077A4 (fr) * 2014-12-19 2018-08-08 The Broad Institute Inc. Ligands des récepteurs dopaminergiques d2
US10450269B1 (en) 2013-11-18 2019-10-22 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10556013B2 (en) 2017-06-20 2020-02-11 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
US11053195B2 (en) 2013-03-15 2021-07-06 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
USRE49110E1 (en) 2008-07-16 2022-06-21 Richter Gedeon Nyrt. Pharmaceutical formulations containing dopamine receptor ligands
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11827618B2 (en) 2019-07-09 2023-11-28 Eli Lilly And Company Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine
US12138254B2 (en) 2018-09-04 2024-11-12 Eli Lilly And Company Chronic nightly dosing of lasmiditan for migraine prevention
US12257246B2 (en) 2009-04-02 2025-03-25 Colucid Pharmaceuticals, Inc. Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl[-benzamide
US12318382B2 (en) 2018-10-17 2025-06-03 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US20040048795A1 (en) * 2002-02-26 2004-03-11 North Shore-Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
EP1613321A2 (fr) * 2003-03-28 2006-01-11 Acadia Pharmaceuticals Inc. Traitement de la douleur au moyen d'agonistes du recepteur muscarinique m1
AU2004264342A1 (en) * 2003-08-05 2005-02-24 Georgetown University Sigma-1 receptor ligand with acetylcholinesterase inhibition properties
US20060247248A1 (en) * 2003-08-05 2006-11-02 Vassilios Papadopoulos Sigma-1 receptor ligand with acetylcholinesterase
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US20160250097A9 (en) * 2004-03-25 2016-09-01 The Feinstein Institute For Medical Research Treatment of inflammation by non-invasive stimulation
CA2560756A1 (fr) * 2004-03-25 2005-10-06 The Feinstein Institute For Medical Research Methodes et dispositifs de reduction de la duree de saignement a l'aide de simulation du nerf vague
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
CA2573673A1 (fr) 2004-07-16 2006-01-26 Proteosys Ag Antagonistes muscariniques avec activite modulatrice parp et sir en tant qu'agents cytoprotecteurs
CA2582615A1 (fr) * 2004-10-05 2006-04-13 Astellas Pharma Inc. Composition pharmaceutique de traitement de l'assechement des liquides lacrymal et salivaire
NZ555320A (en) 2004-12-03 2010-11-26 Schering Corp Substituted piperazines as CB1 antagonists
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
EP2298410B1 (fr) 2004-12-27 2013-10-09 The Feinstein Institute for Medical Research Traitement des troubles inflammatoires par la stimulation électrique du nerf vague
BRPI0613358A8 (pt) * 2005-07-08 2017-12-26 Dsm Ip Assets Bv ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência
WO2007070760A2 (fr) * 2005-12-15 2007-06-21 Boehringer Ingelheim International Gmbh Composes qui modulent le recepteur cb2
US7897601B2 (en) 2006-01-18 2011-03-01 Intervet, Inc. Cannabinoid receptor modulators
WO2007136790A2 (fr) * 2006-05-18 2007-11-29 Mannkind Corporation Inhibiteurs de kinases intracellulaires
EP2081905B1 (fr) * 2006-07-28 2012-09-12 Boehringer Ingelheim International GmbH Composés sulfonyles modulant le récepteur cb2
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
MX2009002888A (es) * 2006-09-25 2009-03-31 Boehringer Ingelheim Int Compuestos que modulan el receptor cb2.
WO2008130616A2 (fr) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines comme modulateurs des récepteurs cb1
ES2601856T3 (es) * 2007-06-08 2017-02-16 Mannkind Corporation Inhibidores de la IRE-1A
CN101790521A (zh) * 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
CN101796033A (zh) * 2007-06-28 2010-08-04 英特维特国际股份有限公司 作为cb1拮抗剂的取代的哌嗪
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
WO2009061652A1 (fr) * 2007-11-07 2009-05-14 Boehringer Ingelheim International Gmbh Composés modulant le récepteur cb2
EP2251011B1 (fr) * 2008-02-21 2012-04-04 Richter Gedeon Nyrt. Préparation solide pour administration orale
WO2009146030A1 (fr) * 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Méthodes et systèmes de réduction d’une inflammation par neuromodulation de l’activité des lymphocytes t
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US20090275997A1 (en) * 2008-05-01 2009-11-05 Michael Allen Faltys Vagus nerve stimulation electrodes and methods of use
WO2009152392A2 (fr) * 2008-06-11 2009-12-17 University Of Toledo Agonistes muscariniques pour troubles neurologiques et procédés pour les préparer
EP2326629B1 (fr) * 2008-07-10 2013-10-02 Boehringer Ingelheim International GmbH Composés sulfones qui modulent le récepteur cb2
NZ591111A (en) * 2008-09-25 2013-08-30 Boehringer Ingelheim Int Sulfonyl compounds which selectively modulate the cb2 receptor
ES2452484T3 (es) * 2008-11-18 2014-04-01 Setpoint Medical Corporation Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria
EP2379080A1 (fr) 2009-01-13 2011-10-26 ProteoSys AG Pirenzépine au titre d'agent otoprotecteur
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
CN102573986B (zh) 2009-06-09 2016-01-20 赛博恩特医疗器械公司 用于无导线刺激器的具有袋部的神经封套
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
US8383615B2 (en) 2009-06-16 2013-02-26 Boehringer Ingelheim International Gmbh Azetidine 2-carboxamide derivatives which modulate the CB2 receptor
EP2480544A1 (fr) * 2009-09-22 2012-08-01 Boehringer Ingelheim International GmbH Composés à modulation sélective du récepteur cb2
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
WO2011079309A2 (fr) * 2009-12-23 2011-06-30 Setpoint Medical Corporation Dispositifs de stimulation neurale et systèmes pour le traitement d'une inflammation chronique
EP2523936A1 (fr) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Composés qui modulent le récepteur cb2
WO2011109324A1 (fr) 2010-03-05 2011-09-09 Boehringer Ingelheim International Gmbh Composés tétrazoles qui modulent sélectivement le récepteur cb2
JP5746764B2 (ja) 2010-07-22 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
US9549928B2 (en) 2011-04-29 2017-01-24 The University Of Toledo Muscarinic agonists as enhancers of cognitive flexibility
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
EP2707094B1 (fr) 2011-05-09 2016-02-03 Setpoint Medical Corporation Activation d'impulsions uniques de la voie anti-inflammatoire cholinergique pour traiter l'inflammation chronique
WO2013068371A1 (fr) 2011-11-08 2013-05-16 Intervet International B.V. Compositions à forme posologique douce à mâcher d'antagonistes des récepteurs de cannabinoïdes de type 1 (cb-1)
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
EP2803668A1 (fr) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Nouveau (cyano-dimethyl-methyl)-isoxazoles et - [1,3,4] thiadiazoles
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (fr) 2015-02-03 2016-08-11 Setpoint Medical Corporation Appareil et procédé de rappel, d'incitation ou d'alerte d'un patient ayant un stimulateur implanté
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
EP3405107B1 (fr) 2016-01-20 2023-04-12 Setpoint Medical Corporation Commande de stimulation vagale
EP3405255A4 (fr) 2016-01-20 2019-10-16 Setpoint Medical Corporation Microstimulateurs implantables et systèmes de recharge par induction
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
CN113939334A (zh) 2019-04-12 2022-01-14 赛博恩特医疗器械公司 迷走神经刺激来处理神经退行性障碍
KR20230012585A (ko) 2020-05-21 2023-01-26 더 파인스타인 인스티튜츠 포 메디칼 리서치 미주 신경 자극을 위한 시스템들 및 방법들
US12444497B2 (en) 2021-05-17 2025-10-14 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2126329A (en) 1936-03-20 1938-08-09 Hoffmann La Roche Amide derivatives of isoxazole carboxylic acids
US2400913A (en) 1944-02-26 1946-05-28 Smith Kline French Lab New composition of matter
US2695295A (en) 1952-12-19 1954-11-23 Mcneilab Inc Unsymmetrical n, n'-substituted ethylenediamine and piperazine compounds
GB874206A (en) 1956-09-05 1961-08-02 Knoll Ag Basic derivatives of salicylamide
BE610830A (fr) 1960-12-01
FR1382425A (fr) 1963-01-14 1964-12-18 Ciba Geigy Procédé de préparation de diaza-cyclo-alcanes, entre autres de la 3-méthyl-4-phényl-1-(2-phénylmercapto-éthyl)-pipérazine
GB1053301A (fr) 1963-01-14
GB1142143A (en) 1965-03-24 1969-02-05 Ferrosan Ab Piperidine-butyrophenones and a process for their production
US3816433A (en) 1965-03-24 1974-06-11 Ferrosan Ab 4-fluoro-ypsilon-(4-methylpiperidino)-butyrophenone and its pharmaceutically acceptable salts
US3488352A (en) 1966-10-11 1970-01-06 Shulton Inc Basically substituted alkoxy anthranilamides,their corresponding 2-nitro compounds and derivatives thereof
FR1543944A (fr) 1967-03-10 1968-10-31 Bruneau & Cie Lab Dérivés amidés de l'acide salicylique et leur préparation
DE2335432A1 (de) 1973-07-12 1975-01-30 Boehringer Mannheim Gmbh 3,4-dihydro-2h-naphthalinon-(1)5-oxy-propyl-piperazin-derivate und verfahren zu ihrer herstellung
BE792187A (fr) 1971-12-03 1973-03-30 Sumitomo Chemical Co Nouveaux derives d'alkylamines
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
GB1459506A (en) 1974-02-18 1976-12-22 Wyeth John & Brother Ltd Piperidine derivatives
GB1498884A (en) 1975-04-15 1978-01-25 Wyeth John & Brother Ltd Aminoacetamide-pyridyl-tetrahydropyridyl and-piperidyl derivatives
US4031101A (en) 1976-04-15 1977-06-21 Parke, Davis & Company Cis-2,6-dimethyl-α,α-diphenyl-1-piperidinebutanol compounds
US4344952A (en) 1980-05-30 1982-08-17 Ab Ferrosan Method of treating diarrhoea with gamma-piperidino-butyrophenones
FR2534912B1 (fr) 1982-10-26 1985-06-28 Lafon Labor Nouveaux derives de (2,4,6-trimethoxyphenyl) - (3-piperidinopropyl) -cetone, utilisation en therapeutique et procede de preparation
US4565821A (en) * 1983-03-21 1986-01-21 The Texas A&M University System Method and ophthalmic composition for treating ocular hypertension and glaucoma with butyrophenones
KR890003966B1 (ko) 1984-05-23 1989-10-14 스미또모 덴끼 고오교 가부시기가이샤 와이어 방전가공용 전극선
US4855290A (en) 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
DE3706585A1 (de) 1987-02-25 1988-09-08 Schering Ag Aryl- und aryloxy-substituierte tert.-alkylenamine, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US4992457A (en) 1987-03-18 1991-02-12 Schulman Jerome M Pharmacologically active cholinergic compositions, and methods for making same and use thereof in treating disease
DE3853758T2 (de) 1987-10-05 1995-09-07 Yamanouchi Pharma Co Ltd Heterozyklische Spiroverbindungen und ihre Herstellung.
US4906634A (en) 1988-03-08 1990-03-06 Schering A.G. Novel N-[4-(aminosubstituted)phenyl]methanesulfonamides and their use as cardiovascular agents
US4838373A (en) 1988-06-30 1989-06-13 Caterpillar Inc. Suspension structure for a tracked vehicle
DE3839385A1 (de) 1988-11-22 1990-05-23 Boehringer Ingelheim Kg Neue quinuclidine, ihre herstellung als arzneimittel und verfahren zu ihrer herstellung
FR2663326B2 (fr) 1989-11-17 1992-10-16 Sanofi Sa Derives de la pyridazine, procede de preparation et compositions pharmaceutiques en contenant.
US5043345A (en) 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
DK178490D0 (da) 1990-07-26 1990-07-26 Novo Nordisk As 1,4-disubstituerede piperaziner
US5276035A (en) 1990-07-26 1994-01-04 Novo Nordisk A/S 1,4-disubstituted piperazines
CA2050264A1 (fr) 1990-08-30 1992-03-01 Raymond Baker Pyrazine a substitution et ses sels, compositions qui en contiennent et leur utilite en medecine
US5093333A (en) 1991-04-29 1992-03-03 American Home Products Corporation N-substituted-2-aminoquinolines useful for treating hypofunction of the cholinergic system
FR2676444B1 (fr) 1991-05-16 1995-03-10 Sanofi Elf Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
EP0591426A4 (en) 1991-06-27 1996-08-21 Univ Virginia Commonwealth Sigma receptor ligands and the use thereof
US5175166A (en) 1991-08-27 1992-12-29 The University Of Toledo Muscarinic agonists
WO1993014089A1 (fr) 1992-01-13 1993-07-22 Novo Nordisk A/S Composes heterocycliques, leur preparation et leur utilisation
US5470850A (en) 1992-02-24 1995-11-28 Novo Nordisk A/S 2,3,4,5-tetrahydro-1H-3-benzazepines
US5716952A (en) 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
DE4234198A1 (de) 1992-10-10 1994-04-14 Boehringer Ingelheim Kg Neue tertiäre Amine mit muskarinischen Eigenschaften
JPH06298732A (ja) 1993-02-16 1994-10-25 Taisho Pharmaceut Co Ltd インドール誘導体
DK26793D0 (da) 1993-03-10 1993-03-10 Novo Nordisk As Benzofuranyl- eller dihydrobenzofuranyl-substituerede tricycliske benzazepiner, der anvendelse og fremstilling
EP1120416A1 (fr) 1993-04-05 2001-08-01 Pharmaceutical Discovery Corporation Pyrido[2.3-b][1,4]benzodiazépinones en tant que ligand de récepteur M2 pour le traitement de troubles neurologiques
JPH06305967A (ja) 1993-04-27 1994-11-01 Taisho Pharmaceut Co Ltd コリン作動性神経不全の改善・治療薬
CA2166100A1 (fr) 1993-06-23 1995-01-05 Richard A. Glennon Ligands de recepteur sigma et leur emploi
JP2983141B2 (ja) 1993-10-06 1999-11-29 株式会社三和化学研究所 新規化合物及び該化合物を有効成分とする脳機能改善剤
FR2717479B1 (fr) 1994-03-18 1996-06-07 Pf Medicament Nouvelles 3-(omega-benzoylpipéridino) alcoyl)-4H-Benzopyran-4-ones, leur préparation et leur application en thérapeutique.
GB9409718D0 (en) 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
WO1996002250A1 (fr) * 1994-07-20 1996-02-01 Acea Pharmaceuticals Inc. Analogues de l'haloperidol et leur utilisation
NZ290199A (en) 1994-07-27 1999-06-29 Sankyo Co Nitrogen containing heterocyclic compounds, selective allosteric effectors to regulate m1 receptors
US5929247A (en) 1994-10-24 1999-07-27 Eli Lilly And Company Heterocyclic compounds and their preparation and use
US5571819A (en) 1994-11-22 1996-11-05 Sabb; Annmarie L. Imidazopyridines as muscarinic agents
US5510478A (en) 1994-11-30 1996-04-23 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5561127A (en) 1994-12-19 1996-10-01 Allelix Biopharmaceuticals, Inc. Muscarinic receptor ligands
US5468875A (en) 1994-12-22 1995-11-21 American Home Products Corporation 1-azabicycloheptane derivatives
TW304167B (fr) 1995-01-30 1997-05-01 Lilly Co Eli
US5605701A (en) 1995-02-17 1997-02-25 Eli Lilly And Company Transdermal formulation
PE17897A1 (es) 1995-02-17 1997-06-12 Lilly Co Eli Formulacion transdermica en parche del 3-(4-butiltio)-1,2,5-tiadiazol-3-il)-1-azabiciclo (2,2,2) octano
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
AU5844796A (en) 1995-05-31 1996-12-18 Yamanouchi Pharmaceutical Co., Ltd. Fused benzodiazepinone derivatives and medicinal composition of the same
US5534522A (en) 1995-06-07 1996-07-09 Warner-Lambert Company (R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agent
BR9608909A (pt) 1995-06-22 1999-03-02 Novo Nordisk As Composto composição farmacêutica processos para estimular a liberação do hormônio do crescimento da patuitária e aumentar a velocidade e extensão do crescimento dos animais para aumentar a produção de leite ou lã de animais ou para para doenças e uso do composto
US5756501A (en) 1995-12-13 1998-05-26 American Home Products Corporation Saturated and unsaturated pyridazino 4,5-B! indolizines useful as antidementia agents
US5726179A (en) 1996-04-01 1998-03-10 The University Of Toledo Muscarinic agonists
EP0900218B1 (fr) 1996-04-23 2002-07-24 Eli Lilly And Company Composes heterocycliques
EP0910566B1 (fr) 1996-04-24 2003-09-17 Novo Nordisk A/S Composes heterocycliques, preparation et utilisation
EP0805153B1 (fr) 1996-04-30 2001-11-14 Pfizer Inc. Agonistes du récepteur muscarinique
AU717431B2 (en) 1996-07-01 2000-03-23 Schering Corporation Muscarinic antagonists
CA2263167C (fr) 1996-08-15 2006-02-14 Schering Corporation Antagonistes muscariniques a base d'ether
US5834458A (en) 1996-10-09 1998-11-10 Eli Lilly And Company Heterocyclic compounds and their use
DE69830840D1 (de) 1997-04-22 2005-08-18 Novo Nordisk As Heterozyklische verbindungen, ihre herstellung und ihre anwendung
EP1017386A1 (fr) 1997-10-02 2000-07-12 H. Lundbeck A/S PREPARATIONS GRANULAIRES DE 5-(2-ETHYLE- 2$i(H)-TETRAZOL- 5-YLE)-1-METHYLE-1, 2,3,6-TETRAHYDROPYRIDINE
CA2326804C (fr) 1998-03-31 2006-05-02 Acadia Pharmaceuticals Inc. Composes presentant une activite sur les recepteurs muscariniques
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors

Cited By (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624162B2 (en) 2001-10-22 2003-09-23 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor modulators
US6979690B2 (en) 2002-01-07 2005-12-27 Pfizer Inc. Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators
US8044207B2 (en) 2002-03-29 2011-10-25 Eli Lilly And Company Pyridinoylpiperidines as 5-HT1F agonists
US8748459B2 (en) 2002-03-29 2014-06-10 Eli Lilly And Company Pyridinoylpiperidines as 5-HT1F agonists
US8829028B2 (en) 2002-05-16 2014-09-09 Serodus As 5-HT4 receptor antagonists for the treatment of heart failure
US6951867B2 (en) 2002-09-20 2005-10-04 Pfizer Inc. N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators
US7012080B2 (en) 2002-09-20 2006-03-14 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor agonists
US7524859B2 (en) 2003-01-06 2009-04-28 Osi Pharmaceuticals, Inc. (2-carboxamido)(3-amino)thiophene compounds
US6949563B2 (en) 2003-01-06 2005-09-27 Graham Michael Wynne (2-carboxamido)(3-amino)thiophene compounds
US7696225B2 (en) 2003-01-06 2010-04-13 Osi Pharmaceuticals, Inc. (2-carboxamido)(3-Amino) thiophene compounds
WO2004063330A2 (fr) 2003-01-06 2004-07-29 Osi Pharmaceuticals, Inc. Composes de (2-carboxamido) (3-amino) thiophene
US7737142B2 (en) 2003-08-04 2010-06-15 Richter Gedeon Vegyeszeti Gyar Rt. (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
US7659394B2 (en) 2004-04-30 2010-02-09 Pfizer Inc Substituted morpholine compounds for the treatment of central nervous system disorders
US7595329B2 (en) 2004-06-15 2009-09-29 Pfizer Inc Benzimidazolone carboxylic acid derivatives
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
US7705020B2 (en) 2004-06-15 2010-04-27 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
WO2006047574A1 (fr) 2004-10-26 2006-05-04 Osi Pharmaceuticals, Inc. Composes de (2-carboxamido)(3-amino) thiophene
US9169224B2 (en) 2004-12-30 2015-10-27 Janssen Pharmaceutica Nv Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
EP2275095A2 (fr) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenese par modulation des recepteurs muscariniques
EP2258359A2 (fr) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
US8097610B2 (en) 2005-08-26 2012-01-17 Shionogi & Co., Ltd. Derivative having PPAR agonistic activity
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2275096A2 (fr) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenese par modulation des recepteurs muscariniques
EP2258358A2 (fr) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
EP2258357A2 (fr) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenèse avec inhibiteur de l'acetylcholinestérase
US8765765B2 (en) 2007-05-18 2014-07-01 Richter Gedeon Nyrt. Metabolites of (thio) carbamoyl-cyclohexane derivatives
US8802672B2 (en) 2007-12-03 2014-08-12 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
US10835532B2 (en) 2008-05-15 2020-11-17 The University Of Toledo Muscarinic agonists as cognitive enhancers
US20140045863A1 (en) * 2008-05-15 2014-02-13 The Board Of Trustees Of The University Of Illinois Muscarinic Agonists as Cognitive Enhancers
USRE49302E1 (en) 2008-07-16 2022-11-15 Richter Gedeon Nyrt. Pharmaceutical formulations containing dopamine receptor ligands
USRE49110E1 (en) 2008-07-16 2022-06-21 Richter Gedeon Nyrt. Pharmaceutical formulations containing dopamine receptor ligands
US8569496B2 (en) 2008-12-17 2013-10-29 Richter Gedeon Nyrt. Piperazine salt and a process for the preparation thereof
US8569497B2 (en) 2008-12-18 2013-10-29 Richter Gedeon Nyrt. Process for the preparation of piperazine derivatives
US8569498B2 (en) 2008-12-18 2013-10-29 Richter Gedeon Nyrt. Process for the preparation of piperazine compounds and hydrochloride salts thereof
US12257246B2 (en) 2009-04-02 2025-03-25 Colucid Pharmaceuticals, Inc. Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl[-benzamide
US8697876B2 (en) 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
US8940745B2 (en) 2010-05-03 2015-01-27 Janssen Pharmaceutica Nv Modulators of fatty acid amide hydrolase
WO2011139951A1 (fr) 2010-05-03 2011-11-10 Janssen Pharmaceutica Nv Modulateurs de l'amide hydrolase d'acide gras
US9688664B2 (en) 2010-05-03 2017-06-27 Janssen Pharmaceutica Nv Modulators of fatty acid amide hydrolase
US9676768B2 (en) 2011-04-21 2017-06-13 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9018214B2 (en) 2011-04-21 2015-04-28 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US11866428B2 (en) 2011-04-21 2024-01-09 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US8912197B2 (en) 2012-08-20 2014-12-16 Forest Laboratories Holdings Ltd. Crystalline form of carbamoyl-cyclohexane derivatives
US9617283B2 (en) 2012-10-19 2017-04-11 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9663512B2 (en) 2012-10-19 2017-05-30 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9617248B2 (en) 2012-10-19 2017-04-11 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US11053195B2 (en) 2013-03-15 2021-07-06 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10450269B1 (en) 2013-11-18 2019-10-22 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9783538B2 (en) 2013-12-20 2017-10-10 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US11643410B2 (en) 2013-12-20 2023-05-09 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US10618895B2 (en) 2013-12-20 2020-04-14 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US12202828B2 (en) 2013-12-20 2025-01-21 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US11225476B2 (en) 2013-12-20 2022-01-18 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US10654842B2 (en) 2014-10-31 2020-05-19 Indivior Uk Limited Dopamine D3 receptor antagonist compounds
US10000477B2 (en) 2014-10-31 2018-06-19 Indivior Uk Limited Dopamine D3 receptor antagonist compounds
US10239870B2 (en) 2014-10-31 2019-03-26 Indivior Uk Limited Dopamine D3 receptor antagonists
US11498896B2 (en) 2014-12-19 2022-11-15 The Broad Institute, Inc. Dopamine D2 receptor ligands
EP3233077A4 (fr) * 2014-12-19 2018-08-08 The Broad Institute Inc. Ligands des récepteurs dopaminergiques d2
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
US12428373B2 (en) 2014-12-19 2025-09-30 The Broad Institute, Inc. Dopamine D2 receptor ligands
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
US10918728B2 (en) 2017-06-20 2021-02-16 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US10953102B2 (en) 2017-06-20 2021-03-23 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US12318453B2 (en) 2017-06-20 2025-06-03 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US11844840B2 (en) 2017-06-20 2023-12-19 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US11376330B2 (en) 2017-06-20 2022-07-05 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US10556013B2 (en) 2017-06-20 2020-02-11 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US12138254B2 (en) 2018-09-04 2024-11-12 Eli Lilly And Company Chronic nightly dosing of lasmiditan for migraine prevention
US12318382B2 (en) 2018-10-17 2025-06-03 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
US12071423B2 (en) 2019-07-09 2024-08-27 Eli Lilly And Company Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate
US11827618B2 (en) 2019-07-09 2023-11-28 Eli Lilly And Company Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate
US12110275B2 (en) 2020-06-30 2024-10-08 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl] piperazin-1-yl]ethyl pyridine-3-carboxylate
US12065410B2 (en) 2020-06-30 2024-08-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11746090B2 (en) 2020-06-30 2023-09-05 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4- trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine
US12285428B2 (en) 2021-05-03 2025-04-29 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Also Published As

Publication number Publication date
US20080108618A1 (en) 2008-05-08
US6528529B1 (en) 2003-03-04
US20030144285A1 (en) 2003-07-31
US7485651B2 (en) 2009-02-03
WO2001005763A3 (fr) 2002-01-17
AU6103000A (en) 2001-02-05

Similar Documents

Publication Publication Date Title
AU762726B2 (en) Compounds with activity on muscarinic receptors
US7485651B2 (en) Compounds with activity on muscarinic receptors
JP4792186B2 (ja) スルホニルカルボキサミド誘導体、その調製方法および医薬としてのその使用
JPH03181461A (ja) 抗不整脈剤
US20040072822A1 (en) N,N-disubstituted diazocycloalkanes
JP2007297410A (ja) ムスカリンアンタゴニスト
DE4101686A1 (de) Indolderivate
AU644296B2 (en) 2-(1-piperidyl)ethanol derivatives, their preparation and their therapeutic application
DE69415391T2 (de) Chinazolinonderivate
JP7104783B2 (ja) ムスカリンｍ１受容体陽性アロステリックモジュレーターであるヘテロアリール化合物
US6362203B1 (en) 4-hydroxy-4-phenylpiperidine derivatives and pharmaceuticals containing the same
EP0441852A1 (fr) Antagonistes recepteurs muscariniques.
CA2543133A1 (fr) Composes presentant une activite sur les recepteurs muscariniques
US6271234B1 (en) 1,4-disubstituted piperazines
EP1978959B1 (fr) Dérivés de pipéridine et de pipérazine
JPH037280A (ja) 新規ベンゾチオピラニルアミン
US7875617B2 (en) 3,4-dihydro-2-naphthamide derivatives as selective dopamine D3 ligands
EP1785415B1 (fr) Dérivé de pipéridine ou sel pharmaceutiquement acceptable de celui-ci
EP0578419B1 (fr) Dérivés de pyridine et compositions pharmaceutiques les contenant
FR2717174A1 (fr) Utilisation de pipéridinoéthyl esters de l'acide 4-amino-5-chloro-2-méthoxybenzoïque comme 5-HT4 agonistes.
JPH0673010A (ja) ピリジン誘導体
CH605924A5 (en) Antidepressant 4-benzofuranyl-piperidine and pyridine derivs.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP